GLP-1 Receptor Agonists: 6 Updated Practice Considerations
Evidence synthesis of weight loss, glycaemic control, and cardiovascular outcomes with GLP-1 receptor agonists and dual incretin therapy in internal medicine practice
One-Minute Takeaway on GLP-1 Receptor Agonists
One-Minute Takeaway
- GLP-1 receptor agonists produce 7–21% mean weight loss across major trials, with tirzepatide (dual GIP/GLP-1) reaching 20.9% at 15 mg in SURMOUNT-1 and semaglutide reaching 14.9% in STEP 1.
- In secondary cardiovascular prevention, semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% (HR 0.80, 95% CI 0.72–0.90) in non-diabetic patients with established cardiovascular disease and BMI ≥ 27 — the SELECT trial.
- A meta-analysis pooling seven cardiovascular outcomes trials in type 2 diabetes demonstrated a 14% MACE reduction (HR 0.86, 95% CI 0.80–0.93) with consistent effects on cardiovascular death, non-fatal myocardial infarction, and stroke.
- The FLOW trial showed a 24% reduction in the kidney composite outcome (HR 0.76, 95% CI 0.66–0.88) in type 2 diabetes with chronic kidney disease, expanding the rationale for prescribing beyond glycaemic and cardiovascular endpoints.
- Gastrointestinal side effects (nausea ~40–50%, vomiting ~15–25%) occur most often during titration; gallbladder events are approximately doubled, and the medullary thyroid carcinoma warning remains based on rodent data without a confirmed human signal.
Why This Topic Matters
Obesity now affects more than 40% of adults in many high-income countries, and type 2 diabetes prevalence continues to rise. For the internal medicine clinician, the rapid evolution of incretin-based pharmacotherapy has shifted what is realistically achievable with medical management of these conditions.
GLP-1 receptor agonists were initially licensed as glucose-lowering drugs in type 2 diabetes. Cardiovascular outcomes trials and dedicated obesity trials have since expanded their evidence base into weight management, cardiovascular risk reduction, and chronic kidney disease.
The arrival of tirzepatide, a unimolecular dual GIP and GLP-1 receptor agonist, has further amplified efficacy. This synthesis brings the major trial evidence on GLP-1 receptor agonists and dual incretin therapy into a single clinical reference framed around the prescribing decisions general internists face: who benefits, what to monitor, what to avoid, and where the evidence remains uncertain.
Evidence Reviewed
This synthesis draws on 13 published sources, anchored by a 2021 Lancet Diabetes & Endocrinology meta-analysis of seven cardiovascular outcomes trials in type 2 diabetes, supplemented by the major dedicated obesity, heart failure, and kidney outcome trials. Only randomised controlled trials and systematic reviews are included for efficacy and safety endpoints.
Table 1 summarises the trial-level evidence used throughout this article. Effect sizes are reported as point estimates with 95% confidence intervals, and population context is included so the reader can judge applicability to their own patients.
| Trial | Drug | Population | n | Primary outcome | Effect (95% CI) |
|---|---|---|---|---|---|
| LEADER | Liraglutide 1.8 mg | T2D + high CV risk | 9,340 | 3-point MACE | HR 0.87 (0.78–0.97) |
| SUSTAIN-6 | Semaglutide SC | T2D + high CV risk | 3,297 | 3-point MACE | HR 0.74 (0.58–0.95) |
| REWIND | Dulaglutide | T2D ± CV disease | 9,901 | 3-point MACE | HR 0.88 (0.79–0.99) |
| PIONEER 6 | Oral semaglutide | T2D + high CV risk | 3,183 | 3-point MACE | HR 0.79 (0.57–1.11) |
| AMPLITUDE-O | Efpeglenatide | T2D + high CV risk | 4,076 | 3-point MACE | HR 0.73 (0.58–0.92) |
| HARMONY OUTCOMES | Albiglutide | T2D + CVD | 9,463 | 3-point MACE | HR 0.78 (0.68–0.90) |
| EXSCEL | Exenatide ER | T2D ± CV disease | 14,752 | 3-point MACE | HR 0.91 (0.83–1.00) |
| ELIXA | Lixisenatide | T2D + recent ACS | 6,068 | 4-point MACE | HR 1.02 (0.89–1.17) |
| STEP 1 | Semaglutide 2.4 mg | Obesity, no T2D | 1,961 | Weight at 68 weeks | −14.9% vs −2.4% |
| SURMOUNT-1 | Tirzepatide 15 mg | Obesity, no T2D | 2,539 | Weight at 72 weeks | −20.9% vs −3.1% |
| SELECT | Semaglutide 2.4 mg | CVD + obesity, no T2D | 17,604 | 3-point MACE | HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg | T2D + CKD | 3,533 | Kidney composite | HR 0.76 (0.66–0.88) |
| STEP-HFpEF | Semaglutide 2.4 mg | HFpEF + obesity | 529 | KCCQ-CSS & weight | ΔKCCQ +7.8 (4.8–10.9) |
Two patterns stand out. First, the early trials with shorter-acting or structurally different molecules (lixisenatide, exenatide ER) showed neutral cardiovascular effects, while long-acting human-analogue molecules produced consistent benefit. Second, the magnitude of cardiometabolic benefit appears to track with both the molecule and the achieved dose intensity.
Key Findings From GLP-1 Receptor Agonists Trials
Weight loss is dose-dependent and exceeds prior pharmacotherapy
Across STEP 1 through STEP 5, semaglutide 2.4 mg weekly produced mean weight reductions of 14.9% to 17.4% at 68–104 weeks in adults with obesity but without diabetes. Tirzepatide demonstrated dose-related effects in SURMOUNT-1, with mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses respectively.
Weight loss with older GLP-1 receptor agonists is smaller. Liraglutide 3.0 mg produces approximately 6–8% weight loss in the SCALE programme, and exenatide and dulaglutide produce 3–5%. The clinical implication is that the molecule chosen substantially determines the achievable effect.
Weight regain after discontinuation is well documented. In STEP 4, withdrawing semaglutide led to recovery of approximately two-thirds of lost weight within one year, supporting the conceptual model of obesity as a chronic disease requiring ongoing therapy rather than a time-limited course.
Cardiovascular benefit is consistent in high-risk type 2 diabetes
The 2021 Sattar et al. meta-analysis, pooling seven cardiovascular outcomes trials in type 2 diabetes, demonstrated a 14% relative reduction in three-point MACE (HR 0.86, 95% CI 0.80–0.93). The effect was directionally consistent across the components: cardiovascular death (HR 0.87), non-fatal myocardial infarction (HR 0.90), and non-fatal stroke (HR 0.83).
Heterogeneity across trials is partly explained by molecular class. Human-analogue long-acting GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, albiglutide, efpeglenatide) demonstrated statistically significant MACE reductions individually, while exendin-4-based agents (lixisenatide, exenatide ER) did not.
The SELECT trial extended the cardiovascular evidence into non-diabetic obesity. In 17,604 adults with established cardiovascular disease and BMI ≥ 27 without diabetes, semaglutide 2.4 mg reduced three-point MACE by 20% (HR 0.80, 95% CI 0.72–0.90) over a mean follow-up of 39.8 months.
Renal and heart failure outcomes broaden the prescribing rationale
The FLOW trial randomised 3,533 adults with type 2 diabetes and chronic kidney disease (eGFR 50–75 with macroalbuminuria, or 25–<50 with any albuminuria) to semaglutide 1.0 mg weekly. The composite kidney outcome — sustained ≥50% eGFR reduction, kidney failure, kidney death, or cardiovascular death — was reduced by 24% (HR 0.76, 95% CI 0.66–0.88).
Heart failure with preserved ejection fraction (HFpEF) in the context of obesity has emerged as a further indication. STEP-HFpEF showed semaglutide 2.4 mg improved KCCQ clinical summary score by 7.8 points and reduced weight by 13.3% versus placebo. The SUMMIT trial extended this signal to tirzepatide in obesity-related HFpEF.
Glycaemic control and progression to diabetes
In type 2 diabetes, HbA1c reductions average 1.0–1.5 percentage points with semaglutide and 1.7–2.4 points with tirzepatide depending on dose, materially exceeding the effect of most oral agents. Hypoglycaemia risk is low when GLP-1 receptor agonists are used without insulin or a sulfonylurea, because insulin secretion is glucose-dependent.
In prediabetes and obesity, secondary analyses of STEP 1 and SURMOUNT-1 found high rates of regression from prediabetes to normoglycaemia. Whether this represents true diabetes prevention or pharmacological suppression that reverses on discontinuation is unresolved by current trial follow-up.
Quality and Consistency
The evidence base supporting GLP-1 receptor agonists is unusually strong for a contemporary drug class, with large dedicated outcomes trials in distinct populations. Consistency varies by domain.
Knowledge Gaps
Specific Evidence Gaps to Acknowledge in Counselling
No dedicated trial has compared tirzepatide with semaglutide for cardiovascular outcomes. The cardiovascular dataset for tirzepatide rests on the SURPASS-CVOT trial which reported non-inferiority versus dulaglutide rather than superiority versus placebo.
Optimal duration of therapy is unknown. Weight regain after discontinuation suggests indefinite treatment is required to maintain benefit, but no trial has evaluated outcomes across decades of continuous use.
Long-term safety data for the medullary thyroid carcinoma signal, pancreatitis, and gallbladder disease beyond five years of continuous exposure remain limited. Pharmacovigilance signals around aspiration during anaesthesia and depressive symptoms are under active regulatory review.
Other unresolved questions include cost-effectiveness in primary prevention obesity, the role of GLP-1 receptor agonists alongside or in place of bariatric surgery, response in adolescents and older adults beyond current trial age ranges, and the long-term clinical meaning of incretin-driven loss of lean body mass.
Equity of access is a system-level concern. List prices for GLP-1 receptor agonists in obesity remain high, supply has been intermittent, and coverage is heterogeneous across health systems, which limits external validity of trial findings to real-world populations.
Practical Implications of GLP-1 Receptor Agonists in Clinic
The findings translate into six practice considerations for internal medicine clinicians prescribing GLP-1 receptor agonists or dual incretin therapy. Each is framed as an evidence-based consideration rather than a directive.
Evidence Supports First-Line Use in T2D with Established or High-Risk CVD
Major society guidelines now prioritise long-acting GLP-1 receptor agonists (or an SGLT2 inhibitor) in type 2 diabetes with established or high-risk atherosclerotic disease, independent of HbA1c, based on consistent MACE reduction across CVOTs.
Evidence Supports Semaglutide 2.4 mg for Secondary CV Prevention in CVD + Obesity
SELECT extends benefit to non-diabetic patients with established cardiovascular disease and BMI ≥ 27. Eligible patients without contraindications can be offered this option for cardiovascular risk reduction in addition to lifestyle and statin therapy.
Evidence Shows Tirzepatide Produces Larger Weight Reductions than Semaglutide
SURMOUNT-5 head-to-head data indicate tirzepatide is more potent for weight loss than semaglutide 2.4 mg. Tirzepatide lacks a dedicated obesity-CV outcomes trial, so molecule choice should weigh weight goals against accumulated outcomes evidence.
Evidence Indicates Slow Titration Mitigates GI Tolerability Issues
Approximately 40–50% of patients experience nausea during dose escalation. Standard four-step titration over 16–20 weeks, small frequent meals, and slowing or holding a dose at intolerance reduce discontinuation.
Evidence Justifies Routine Monitoring of Specific Parameters
Track weight, blood pressure, HbA1c (where relevant), renal function, and lipid profile. Screen for symptoms of pancreatitis or gallbladder disease at each visit. Confirm contraception in patients of reproductive potential.
Evidence Defines Clear Contraindications and Cautions
Avoid in personal or family history of medullary thyroid carcinoma and in multiple endocrine neoplasia type 2. Use with caution after acute pancreatitis, in severe gastroparesis, and before elective anaesthesia (per current ASA guidance on perioperative holding).
Adverse-Effect Profile and Counselling Points
Across STEP and SURMOUNT trials, nausea occurred in roughly 40–50% of participants on GLP-1 receptor agonists, vomiting in 15–25%, diarrhoea in 20–30%, and constipation in 10–20%. The majority were mild to moderate and concentrated in the titration phase.
Practical mitigation includes slow titration, small frequent low-fat meals, avoiding alcohol and high-fat foods during escalation, and holding the current dose if intolerable rather than reducing it abruptly.
Pooled analyses indicate an approximately two-fold increased risk of biliary disease (cholelithiasis, cholecystitis) with GLP-1 receptor agonists, partly attributable to rapid weight loss. Absolute risk in trial populations remained low (roughly 1.5–2.5%).
Acute pancreatitis was reported numerically more often in early trials, but pooled CVOT data have not confirmed a statistically significant excess. Re-evaluate risk in patients with prior pancreatitis or gallstones.
Rodent studies showed dose-dependent C-cell tumour formation, which led to the contraindication in personal or family history of medullary thyroid carcinoma and MEN 2. Human pharmacoepidemiology to date has not confirmed an increased medullary thyroid carcinoma incidence, though follow-up duration remains shorter than the latency of these rare cancers.
Delayed gastric emptying with GLP-1 receptor agonists has been associated with retained gastric contents at endoscopy and isolated case reports of aspiration under anaesthesia. Current society guidance suggests considering holding weekly agents one week before elective procedures requiring deep sedation or general anaesthesia, while individualising for diabetes control.
GLP-1 receptor agonists are not recommended during pregnancy and should be discontinued at least two months before planned conception (longer for longer-acting agents). Counsel reliable contraception in patients of reproductive potential and document fertility return associated with weight loss, which can be substantial.
Evidence Grade and Bottom Line
Overall Evidence Grade: Strong for MACE reduction in type 2 diabetes with high cardiovascular risk and for weight loss in obesity; Strong for the SELECT non-diabetic CVD + obesity indication based on one large adequately powered trial pending replication; Moderate for kidney composite outcomes in T2D with CKD; Moderate for symptomatic improvement in obesity-related HFpEF; Limited for primary cardiovascular prevention in low-risk populations.
Bottom Line
- GLP-1 receptor agonists have crossed from glucose-lowering drugs into a broader cardiometabolic risk-reduction class and are now first-line in type 2 diabetes with established or high-risk cardiovascular disease.
- The SELECT trial extends cardiovascular benefit to non-diabetic patients with established cardiovascular disease and BMI at least 27, with a 20% relative reduction in MACE.
- Tirzepatide produces the largest pharmacological weight reductions reported in adults with obesity short of bariatric surgery, but lacks a dedicated obesity-cardiovascular outcomes trial.
- Tolerability, durability, and cost remain practical limitations; weight regain after discontinuation supports framing therapy as chronic rather than time-limited.
- Long-term safety beyond five years and equity of access are open questions that should be acknowledged in shared decision-making with patients.
Article Information and References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. DOI: 10.1056/NEJMoa1603827
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. DOI: 10.1056/NEJMoa1607141
- Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). N Engl J Med. 2019;381(9):841-851. DOI: 10.1056/NEJMoa1901118
- Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes (AMPLITUDE-O). N Engl J Med. 2021;385(10):896-907. DOI: 10.1056/NEJMoa2108269
- Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (HARMONY OUTCOMES). Lancet. 2018;392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X
- Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med. 2015;373(23):2247-2257. DOI: 10.1056/NEJMoa1509225
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. DOI: 10.1056/NEJMoa2403347
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084. DOI: 10.1056/NEJMoa2306963